However, although the strategy of extended TMZ treatment dramatically improved the PFS of newly diagnosed GBM patients with higher expression of Ki67 (8.80 months vs. 12.90 months, HR = 2.60, 95% CI: 1.34 ~ 5.03, P < 0.001), it did not significantly improve the PFS in the population with lower Ki67 expression (11.50 months vs. 15.10 months, HR = 1.35, 95% CI: 0.72 ~ 2.52, P = 0.318) (Figure 7B). The gene discussed is MKI67; the disease is glioblastoma.